Update on psychotropic medication use in renal disease

被引:35
作者
Cohen, LM
Tessier, EG
Germain, MJ
Levy, NB
机构
[1] Baystate Med Ctr, Tufts Univ, Sch Med, Psychiat Consultat Serv, Springfield, MA 01199 USA
[2] Baystate Med Ctr, Renal Transplantat Serv, Springfield, MA 01199 USA
[3] Tufts Univ, Sch Med, Dept Psychiat, Boston, MA 02111 USA
[4] Springfield Coll, Phys Assistant Program, Springfield, MA USA
[5] ARxGOS Consulting, Keene, NH USA
[6] Kingsboro Psychiat Ctr, Brooklyn, NY USA
关键词
D O I
10.1176/appi.psy.45.1.34
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Renal failure is a common medical condition, and many patients have comorbid psychiatric disorders. In this review, which is intended as a resource for consultation psychiatrists, the authors discuss pharmacokinetic considerations and provide information about the use of individual psychotropic medications in patients with renal disease. Most psychotropic medications are fat soluble, easily pass the blood-brain barrier, are not dialyzable, are metabolized primarily by the liver, and are excreted mainly in bile. Consequently, the majority of these drugs can be safely used with the end-stage renal disease population.
引用
收藏
页码:34 / 48
页数:15
相关论文
共 99 条
[1]  
*ABB LAB, 1999, PROD INF DEP VALPR A
[2]   CLINICAL PHARMACOKINETICS OF FLUOXETINE [J].
ALTAMURA, AC ;
MORO, AR ;
PERCUDANI, M .
CLINICAL PHARMACOKINETICS, 1994, 26 (03) :201-214
[3]  
AMIEL M, 1987, J CLIN PSYCHIAT, V48, P424
[4]  
[Anonymous], PHYS DESK REF
[5]  
[Anonymous], 1999, Drug Prescribing in Renal Failure
[6]  
*ASTR PHARM, 2000, PROD INF SER QUET
[7]   PROLONGED SEDATION DUE TO ACCUMULATION OF CONJUGATED METABOLITES OF MIDAZOLAM [J].
BAUER, TM ;
RITZ, R ;
HABERTHUR, C ;
HA, HR ;
HUNKELER, W ;
SLEIGHT, AJ ;
SCOLLOLAVIZZARI, G ;
HAEFELI, WE .
LANCET, 1995, 346 (8968) :145-147
[8]   Fluoxetine in depressed patients on dialysis [J].
Blumenfield, M ;
Levy, NB ;
Spinowitz, B ;
Charytan, C ;
Beasley, CM ;
Dubey, AK ;
Solomon, RJ ;
Todd, R ;
Goodman, A ;
Bergstrom, RF .
INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE, 1997, 27 (01) :71-80
[9]  
BRADEN GL, 2001, PRIMER KIDNEY DIS, P322
[10]  
BRATER DC, 1999, THERAPY NEPHROLOGY H, P641